Aberrations in the Iron Regulatory Gene Signature Are Associated with Decreased Survival in Diffuse Infiltrating Gliomas
| Autor: | James R. Connor, Jennifer Weston, Steven A. Toms, Nicholas F. Marko, Cody Weston, Joe Klobusicky |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Male Pathology Gene Expression lcsh:Medicine Kaplan-Meier Estimate Transcriptome Diffusion Prostate cancer 0302 clinical medicine Mathematical and Statistical Techniques Breast Tumors Medicine and Health Sciences Blastomas lcsh:Science Neurological Tumors Regulator gene Regulation of gene expression Multidisciplinary Applied Mathematics Simulation and Modeling Glioma Genomics Phenotype Chemistry Oncology Neurology 030220 oncology & carcinogenesis Physical Sciences Statistics (Mathematics) Algorithms Research Article Chemical Elements medicine.medical_specialty Iron Biology Research and Analysis Methods 03 medical and health sciences Breast cancer Breast Cancer medicine Genetics Humans Gene Regulation Statistical Methods Gene Retrospective Studies lcsh:R Cancers and Neoplasms Biology and Life Sciences medicine.disease 030104 developmental biology Cancer research lcsh:Q Glioblastoma Multiforme Mathematics Forecasting |
| Zdroj: | PLoS ONE, Vol 11, Iss 11, p e0166593 (2016) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | Iron is a tightly regulated micronutrient with no physiologic means of elimination and is necessary for cell division in normal tissue. Recent evidence suggests that dysregulation of iron regulatory proteins may play a role in cancer pathophysiology. We use public data from The Cancer Genome Atlas (TCGA) to study the association between survival and expression levels of 61 genes coding for iron regulatory proteins in patients with World Health Organization Grade II-III gliomas. Using a feature selection algorithm we identified a novel, optimized subset of eight iron regulatory genes (STEAP3, HFE, TMPRSS6, SFXN1, TFRC, UROS, SLC11A2, and STEAP4) whose differential expression defines two phenotypic groups with median survival differences of 52.3 months for patients with grade II gliomas (25.9 vs. 78.2 months, p< 10-3), 43.5 months for patients with grade III gliomas (43.9 vs. 87.4 months, p = 0.025), and 54.0 months when considering both grade II and III gliomas (79.9 vs. 25.9 months, p < 10-5). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|